Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia

Haematologica

Volumn 96, Issue 12, 2011, Pages 1874-1877

  Grossmann, Vera ^a   Kern, Wolfgang ^a   Harbich, Stefan ^a   Alpermann, Tamara ^a   Jeromin, Sabine ^a   Schnittger, Susanne ^a   Haferlach, Claudia ^a   Haferlach, Torsten ^a   Kohlmann, Alexander ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

Prognosis; RUNX1 mutations; T cell ALL

Indexed keywords

TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; ARTICLE; BONE MARROW; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FRAMESHIFT MUTATION; GENE; GENE INSERTION; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATION RATE; MUTATIONAL ANALYSIS; NONSENSE MUTATION; OVERALL SURVIVAL; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROGNOSIS; RUNX1 GENE; SEQUENCE ANALYSIS;

ADULT; AGE FACTORS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DISEASE-FREE SURVIVAL; FEMALE; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; MUTATION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL RATE;

EID: 82855168093     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.043919     Document Type: Article

References (24)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lympoid tissues. Lyon, France: IARC;2008.
2. Zhao WL. Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia. 2010;24(1):13-21.
3. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9(10): 1783-6.
4. Gokbuget N, Hoelzer D, Arnold R, Bohme A, Bartram CR, Freund M, et al. Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2000;14(6):1307-25.
5. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551-65.
6. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1(2):133-43.
7. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-64.
8. Baldus CD, Martus P, Burmeister T, Schwartz S, Gokbuget N, Bloomfield CD, et al. Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol. 2007;25(24):3739-45.
9. Wong WF, Kohu K, Chiba T, Sato T, Satake M. Interplay of transcription factors in T-cell differentiation and function: the role of Runx. Immunology. 2011;132(2):157-64.
10. Cohen MM Jr. Perspectives on RUNX genes: an update. Am J Med Genet A. 2009;149A (12):2629-46.
11. Schnittger S, Dicker F, Kern W, Wendland N, Sundermann J, Alpermann T, et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood. 2011;117(8): 2348-57.
12. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood. 2004;103(6):2316-24.
13. Kuo MC, Liang DC, Huang CF, Shih YS, Wu JH, Lin TL, et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia. 2009;23(8):1426-31.
14. Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Rock J, Paschka P, et al. RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group. J Clin Oncol. 2011; 29(10):1364-72.
15. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: An Update. J Clin Oncol. 2011;29(5):551-65.
16. De Braekeleer E, Douet-Guilbert N, Morel F, Le Bris MJ, Férec C, De Braekeleer M. RUNX1 translocations and fusion genes in malignant hemopathies. Future Oncol. 2011;7(1):77-91.
17. Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011;25(3):557-60.
18. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 2004;104(10):3078-85.
19. Chiaretti S, Foa R. T-cell acute lymphoblastic leukemia. Haematologica 2009;94(2):160-2.
20. Appelmann I, Linden T, Rudat A, Mueller-Tidow C, Berdel WE, Mesters RM. Hereditary thrombocytopenia and acute myeloid leukemia: a common link due to a germline mutation in the AML1 gene. Ann Hematol. 2009;88(10):1037-8.
21. Ito Y. Oncogenic potential of the RUNX gene family: 'overview'. Oncogene. 2004; 23(24):4198-208.
22. Dicker F, Haferlach C, Sundermann J, Wendland N, Weiss T, Kern W, et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia. 2010;24(8):1528-32.
23. Kohlmann A, Grossmann V, Schindela S, Kern W, Haferlach C, Haferlach T, et al. Ultra-Deep Next-Generation Sequencing Detects RUNX1 Mutations with Unprecedented Sensitivity and Allows to Monitor Minimal Residual Disease In 116 Samples From MDS and AML Patients Clinically Relevant Abstract. Blood. 2010; 116(21):1691a.
24. Droese J, Langerak AW, Groenen PJ, Bruggemann M, Neumann P, Wolvers- Tettero IL, et al. Validation of BIOMED-2 multiplex PCR tubes for detection of TCRB gene rearrangements in T-cell malignancies. Leukemia. 2004;18(9):1531-8.